52 Week Range
As of on the New York Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Thermo Fisher Reports Q1 Earnings Of $5.88 Per Share
Thermo Fisher Scientific To Acquire PPD, Inc., A Leading Clinical Research Organization
Thermo Fisher Nears Deal To Buy PPD For More Than $15 Billion- WSJ
Thermo Fisher Scientific Inc. develops, manufactures and sells a range of products. The Company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. It offers its products and services through various brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services. Life Sciences Solutions segment provides a portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines. Analytical Instruments segment provides a broad offering of instruments, consumables, software and services that are used for a range of applications in the laboratory. Specialty Diagnostics segment offers a wide range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Services segment offers products and solutions needed for the laboratory.
Medical Equipment & Supplies
168 3rd Ave
Marc N. Casper
Chairman of the Board, President, Chief Executive Officer
Chief Financial Officer, Senior Vice President
Chief Operating Officer, Executive Vice President
Executive Vice President
Michael A. Boxer
Senior Vice President, General Counsel
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Thermo Fisher Scientific Inc beat first-quarter profit estimates on Thursday as strong sales of materials used to make COVID-19 vaccines and treatments helped offset slowing demand for tests that detect the novel coronavirus.
Thermo Fisher Scientific Inc on Thursday posted quarterly profit that nearly tripled, helped by increased demand for its COVID-19 tests and a jump in sales at its life sciences unit.
Medical device maker Thermo Fisher Scientific Inc said on Thursday it would acquire contract researcher PPD Inc for $17.4 billion as it looks to add more muscle to its pharmaceutical services business.
Cravath, Swaine & Moore and Arnold & Porter Kaye Scholer are guiding medical device maker Thermo Fisher Scientific Inc in its $17.4 billion cash acquisition of drug testing company PPD Inc, which turned to Simpson, Thacher & Bartlett.
Thermo Fisher Scientific Inc on Thursday said it would acquire contract research firm PPD Inc for about $20.9 billion, including net debt. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Bernard Orr)
Medical device company Thermo Fisher Scientific is nearing a deal to buy contract research firm PPD Inc for more than $15 billion, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
Thermo Fisher Scientific is nearing a deal to buy PPD Inc for more than $15 billion, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
Thermo Fisher Scientific said on Thursday it would work with Pfizer and BioNtech to produce their COVID-19 vaccine in Italy.
A plant in Belgium said to be the main cause of big cuts in AstraZeneca's COVID-19 vaccine supplies to the European Union said on Wednesday it had complied with all its obligations under a contract it has with the Anglo-Swedish firm.
Genetic testing specialist Qiagen's Chief Executive Thierry Bernard said the company is interested in organic growth and "bolt-on" acquisitions, when asked about recent merger and acquisition speculation during a results conference call on Wednesday.
Thermo Fisher Scientific Inc on Monday forecast 2021 profit above market estimates and posted better-than-expected quarterly earnings as it continues to gain from upbeat demand for its COVID-19 tests and materials for vaccine production.
Thermo Fisher Scientific Inc, the world's largest maker of scientific instruments, on Monday forecast 2021 profit above market estimates as it continues to gain from upbeat demand for its COVID-19 tests and materials for vaccine production.
Thermo Fisher Scientific Inc said on Friday it completed its 725 million euros ($879.72 million) acquisition of Belgium-based Henogen SA that will help strengthen the medical device maker's position in the fast-growing field of gene therapy manufacturing.
Medical device maker Thermo Fisher Scientific Inc said on Friday it has completed acquisition of Henogen SA, a Belgium-based viral vector manufacturing business, for about 725 million euros ($879.72 million) in cash.
The University of Oxford has partnered with U.S.-based Thermo Fisher Scientific to ramp up its capacity to deliver COVID-19 testing data and help collect and quantify immune responses in its vaccine trials, the university said on Tuesday.
Inovio Pharmaceuticals Inc said on Tuesday that Thermo Fisher Scientific would manufacture the drug developer's experimental coronavirus vaccine, as it looks to boost the supply ahead of large trials this month.
Inovio Pharmaceuticals Inc said on Tuesday that Thermo Fisher Scientific would manufacture its experimental coronavirus vaccine to boost the supply of the vaccine.
Qiagen <QIA.DE> said its non-executive Chairman Hakan Bjoerklund had resigned with immediate effect after the genetic testing company's shareholders rejected an improved takeover offer from Thermo Fisher <TMO.N>.
Thermo Fisher <TMO.N> has walked away from its takeover deal with Qiagen <QIA.DE> after the German genetic testing specialist's earnings were boosted by coronavirus diagnostics, leaving its shareholders reluctant to cash out.
Thermo Fisher Scientific said on Thursday it has terminated its acquisition agreement for German genetic testing company Qiagen as the minimum acceptance threshold to its tender offer were not met. Thermo Fisher's revised offer had valued Qiagen at 11.3 billion euros ($13.38...
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.